eMedicine Specialties > Urology > Surgery

Nephrectomy, Radical: Treatment

Author: Richard A Santucci, MD, FACS, Chief of Urology, Detroit Receiving Hospital; Specialist-in-Chief of Urology, Detroit Medical Center; Chief of Urologic Trauma Surgery, Sinai Grace Hospital; Director, The Center for Urologic Reconstruction; Clinical Professor of Urology, Michigan State College of Medicine
Coauthor(s): Hosam S Al-Qudah, MD, Consultant Urologist, Department of General Surgery, Saad Specialist Hospital, Al-Khobar, Saudi Arabia
Contributor Information and Disclosures

Updated: Nov 24, 2009

Treatment

Medical Therapy

Radical nephrectomy has been the traditional approach to treating solid renal masses. However, not all solid renal masses are malignant. As the number of incidentally detected solid renal masses increases because of widespread radiographic imaging, the incidence of benign tumors appears to be increasing.

In a prospective study of 106 solid renal masses treated with surgical resection, Dechet et al showed that 15 (14%) were benign.7 Oncocytomas compromised most masses, with an overall 10% incidence rate of solid renal masses. Given the high incidence of benign tumors, especially among solid renal masses 4 cm in diameter or smaller, radical nephrectomy seems excessive in all cases. However, identifying these cases preoperatively using radiographic imaging and/or fine-needle biopsy or aspiration is impossible.

Link et al reviewed the results of 223 laparoscopic partial nephrectomies and found that only 66.4% of patients had renal cell cancer in the final pathology (mean tumor size, 2.6 cm).8 Some centers advocate intraoperative needle biopsy of these solid renal masses with immediate frozen-tissue sectioning to help identify patients who may benefit from NSS or radical nephrectomy if specific tumor histology can be determined.

A urologist should seek a tissue diagnosis only if an indeterminate or solid lesion is found in a patient with known nonrenal cancer (ie, differential diagnosis of primary renal cancer vs a metastatic lesion). In rare cases, tumors have an infiltrating pattern on CT scans and are suspicious for lymphoma. In this regard, an ultrasound-guided or CT-guided puncture or biopsy of the lesion is indicated.

Surgical Therapy

Radical nephrectomy of the kidney is the treatment of choice for stage I, II, and some stage III tumors.

Radical nephrectomy encompasses ligating the renal artery and vein, removing the kidney outside the Gerota fascia, removing the ipsilateral adrenal gland, and performing a complete regional lymphadenectomy from the crus of the diaphragm to the aortic bifurcation.

The surgical approach includes either a transperitoneal incision (extended or bilateral subcostal and thoracoabdominal) or an extraperitoneal incision, depending on the size and location of the tumor and the patient's habitus. Cardiopulmonary bypass with deep hypothermic circulatory arrest is used is performed in patients with supradiaphragmatic tumor thrombi involvement.

The surgical approach is guided more by individual preference than by necessity. In some institutions, a midline incision is commonly used, while, in others, the anterior subcostal, thoracoabdominal, and flank approaches are preferred. In general, most tumors are resectable through a transperitoneal subcostal incision.

The principal advantage of the abdominal approach is that exposure in the area of the renal pedicle is excellent. A vertical midline incision is easier and quicker to perform. It also allows better access for inspection of the remainder of the abdominal contents. A transverse incision provides better access to the lateral and superior portion of the kidney, and a unilateral subcostal incision can be extended across the midline as a chevron incision to provide excellent exposure of both kidneys, the aorta, and the inferior vena cava. The principal disadvantage of the abdominal approach is the somewhat longer period of postoperative ileus and intra-abdominal adhesions.

Removal of the adrenal gland has been advocated because the gland is enclosed within the Gerota fascia and because ipsilateral adrenal metastasis occurs in 2-10% of most reported series.9 The risk of adrenal metastasis is related to the malignant potential of the primary tumor and its size and position. The need for routine ipsilateral adrenalectomy currently is under debate. A new report of 247 patients with RCC showed that only 3% of patients had adrenal involvement; each case was diagnosed preoperatively with CT scanning.10 However, patients with large tumors or tumors high in the upper pole are probably better served with a standard radical nephrectomy that includes adrenalectomy.

The role of regional lymphadenectomy in patients with localized kidney cancer is controversial. Because no widely effective treatments are available for metastatic RCC, proponents argue that if only small nodes are involved, regional lymphadenectomy may benefit a small number of patients. Extensive nodal involvement portends a poor prognosis. Patients with lymphatic metastasis commonly demonstrate synchronous or metachronous distant metastasis; thus, regional lymphadenectomy is of no benefit. Despite a lack of randomized controlled studies, current data suggest that some patients can benefit from regional lymphadenectomy, especially the subset of patients with micrometastatic lymph node involvement.

Preoperative Details

In addition to a good history and physical examination, certain tests are performed routinely prior to any major renal surgery. These include ECG, chest radiography, complete blood cell count, and electrolyte profile with BUN and creatinine levels.

Preoperative pulmonary function testing and blood gas analysis are necessary in patients in whom impaired respiratory function is suspected. A flank position with lateral flexion of the spine can decrease ventilatory capacity and venous return, resulting in hypotension and hypoxia. Thus, an anterior surgical approach with the patient in the supine position is used in patients with significantly impaired respiratory function. Preoperative breathing exercises, alleviation of bronchospasm, and cessation of smoking help prevent postoperative cardiorespiratory problems.

Patients should be asked about any use of alcohol or the ingestion of drugs or aspirin that may influence blood clotting. Prothrombin time, activated partial thromboplastin time, and a platelet count are used routinely to identify bleeding tendencies.

The anatomy of the urinary tract is usually examined prior to any nephrectomy. These studies include intravenous pyelography, cystoscopy, retrograde pyelography, ureteroscopy, cystourethrography, CT scanning, ultrasonography, MRI, renal angiography, and renal venography. These tests reveal the location of the kidneys; any anatomic variations such as a duplicated ureter, horseshoe kidneys, or multiple arteries or veins; and associated pathology such as renal stones, transitional cell carcinomas of the bladder or ureter, and possible lesions of the contralateral (ie, remaining) kidney.

CT scanning is the most cost-effective method of evaluating a suspected renal mass lesion and is currently the method of choice for detecting and staging renal carcinoma.

Differential renal function is often assessed noninvasively with computerized isotope renography (renal scan) using radioactive iodine (iodine 131) or technetium-99m.

Organism-specific antibiotic therapy is instituted at least 48 hours after surgery if the patient has evidence of an upper or lower urinary tract infection.

Preoperative percutaneous embolization of the kidney is occasionally rendered for patients with an arterialized vena cava thrombus or if medial extension of the tumor interferes with early ligation of the renal artery. Angioinfarction commonly leads to transient flank pain, which requires analgesic medication.

Intraoperative Details

An anterior subcostal, thoracoabdominal, or flank approach is used depending on the size and location of the tumor and the habitus of the patient.

An extraperitoneal flank approach is usually preferable when the kidney is chronically infected, when the patient is obese, or when multiple prior abdominal operations have been performed.

A transperitoneal approach is preferable in patients who tolerate flank position, in patients with end-stage renal disease undergoing bilateral nephrectomy for polycystic kidney disease, and in patients with traumatic renal injuries in whom early access to the pedicle is necessary.

The transperitoneal subcostal incision is used to resect most renal tumors because exposure to the great vessels through this approach is excellent. A large upper-pole tumor is best approached via the thoracoabdominal route. After the peritoneal cavity is entered, the intra-abdominal contents are inspected for any evidence of metastatic disease. The peritoneal reflection is incised along the line of Toldt, thus mobilizing the ascending and descending colon.

The vena cava is used as a reference landmark with tumors of the right kidney. This vessel can be followed upward to the point where the left renal vein enters. Before dealing with the renal vessels, ligating and dissecting the gonadal vein at the point where it enters the vena cava is preferable. Then, the renal artery and vein are ligated and divided. The renal artery is ligated before the vein whenever possible, on either side. However, approaching the pedicle from the front, to ligate and divide the vein first, is sometimes easier. After this, the artery is readily exposed and quickly clamped and ligated. Downward and lateral traction of the kidney exposes the superior vascular attachments of the tumor and adrenal gland. Exposure of these vessels also is facilitated by medial retraction of the inferior vena cava.

The right renal artery can be ligated in the aortocaval space. This is especially useful when regional lymphadenectomy is performed because the access to this space must be obtained anyway. Usually, the renal artery is ligated with two 2-0 nonabsorbable ligatures close to the aorta. A ligature is also placed in the distal end. The renal vein is palpated for any firmness that suggests a tumor thrombus. Short adrenal veins that empty directly into the side of the vena cava may also need ligature or hemostasis. Lumbar veins are usually not clipped because they may become displaced. Instead, a 0 silk ligature is passed on a right-angle clamp and tied. Oversewing the stumps of the renal artery and vein with 5-0 arterial silk may be prudent.

Some surgeons prefer to doubly clamp the artery and vein separately and to divide it between clamps. After removing the specimen, the artery is tied with 1-0 synthetic absorbable suture (SAS) and reinforced with a second 1-0 SAS as a stick tie. The vein is ligated with a 1-0 SAS.

Tumor extension into the renal vein usually is not problematic because the tumor thrombus can be milked back toward the kidney as the renal vein is ligated closer to the vena cava. Occasionally, a vascular clamp must be placed at the junction of the renal vein and inferior vena cava. Then, the renal vein is divided, the vein and thrombus resected, and the stump of the renal vein or caval incision is oversewn. Management of tumor thrombus within the inferior vena cava depends on the cephalad extent of the thrombus and the presence or absence of invasion into the inferior vena cava.

Then, the Gerota fascia surrounding the kidney and adrenal gland is dissected away from the surrounding structures using sharp and blunt dissection, as needed. Lymphatic and sympathetic structures are ligated or clipped. The ureter and gonadal vein are mobilized bluntly to the level of bifurcation of the aorta and lifted into the wound. Each is clamped and ligated with 0 silk ligatures, leaving the proximal end long enough for later identification.

The upper pole of the kidney is pulled down to expose the adrenal gland, and the connective tissue and peritoneal attachments are progressively divided. Starting the dissection laterally along the posterior body wall toward the crus of the diaphragm is easier. The cranial connections to the adrenal gland are divided carefully between clips. In 75% of cases, ipsilateral adrenalectomy is not required. For left-sided tumors, the splenocolic and lienophrenic attachments are divided to allow the spleen to be swung up out of the way; otherwise, the spleen may be injured during a left nephrectomy from an anterior approach.

The kidney is removed from the retroperitoneum. Regional lymphadenectomy for RCC is controversial. The defect in the mesocolon is closed to prevent internal hernias.

Renal tumor after surgical removal.

Renal tumor after surgical removal.

Renal tumor after surgical removal.

Renal tumor after surgical removal.


Drains are not used routinely for radical nephrectomy at the authors' institution. However, if the intraoperative blood pressure is low, later bleeding from spasmic small vessels is anticipated.

Direct infiltration into the duodenum and the wall of the colon is rare. If the colon or the spleen is involved, consider removing the organ. If locally advanced tumors suspected of extension into either the colon or mesentery are present, patients should undergo a mechanical and antibiotic bowel preparation. Segmental colon resection and primary anastomosis should be possible in most cases. Invasion of the liver is uncommon because of the Glisson capsule, which forms a barrier. For invasion of the liver, perform right hepatectomy and right nephrectomy en bloc by controlling the hilar structures on the right side first. The mass then can be elevated to expose the vena cava to allow control of the hepatic veins. If the tail of the pancreas is involved from left-sided kidney cancer, perform simple resection of the tail of the pancreas and oversew the pancreatic duct, covering the resected area with greater omentum.

Postoperative Details

Many postoperative complications, such as myocardial infarction, cerebrovascular accident, congestive heart failure, pulmonary embolism, atelectasis, pneumonia, and thrombophlebitis, can be reduced with adequate preoperative preparation, avoidance of intraoperative hypotension, appropriate blood and fluid replacement, postoperative breathing exercises, early mobilization, and elastic support of the legs, both during and after surgery.

After nephrectomy for unilateral renal disease, the opposite normal kidney undergoes compensatory hypertrophy, and the glomerular filtration rate is ultimately maintained at 75% of the normal value. Normal life expectancy can be achieved after a unilateral nephrectomy with a normal contralateral kidney.

Complications

Approximately 20% of patients undergoing radical nephrectomy develop postoperative complications, and the operative mortality rate is approximately 2%.

Intraoperative complications include injury to any gastrointestinal organs (eg, liver, spleen, pancreas) or to any major blood vessels (eg, aorta, inferior vena cava). Pleural injuries can result in pneumothorax.

Postoperative complications include secondary hemorrhage from the renal pedicle or any unrecognized injury, atelectasis, ileus, both superficial and deep wound infections, temporary or permanent renal failure, and incisional hernia.

Other well-recognized systemic complications include myocardial infarction, congestive heart failure, pulmonary embolism, cerebrovascular accident, pneumonia, and thrombophlebitis.

More on Nephrectomy, Radical

Overview: Nephrectomy, Radical
Workup: Nephrectomy, Radical
Treatment: Nephrectomy, Radical
Follow-up: Nephrectomy, Radical
Multimedia: Nephrectomy, Radical
References

References

  1. Robson CJ. Radical nephrectomy for renal cell carcinoma. J Urol. Jan 1963;89:37-42. [Medline].

  2. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol. Dec 2006;176(6 Pt 1):2353-8. [Medline].

  3. Sudarshan S, Linehan WM. Genetic basis of cancer of the kidney. Semin Oncol. Oct 2006;33(5):544-51. [Medline].

  4. Novick AC, Stewart BH, Straffon RA, Banowsky LH. Partial nephrectomy in the treatment of renal adenocarcinoma. J Urol. Dec 1977;118(6):932-6. [Medline].

  5. Glazer A, Novick AC. Preoperative transesophageal echocardiography for assessment of vena caval tumor thrombi: a comparative study with venacavography and magnetic resonance imaging. Urology. Jan 1997;49(1):32-4. [Medline].

  6. Subramanian VS, Stephenson AJ, Goldfarb DA, Fergany AF, Novick AC, Krishnamurthi V. Utility of preoperative renal artery embolization for management of renal tumors with inferior vena caval thrombi. Urology. Jul 2009;74(1):154-9. [Medline].

  7. Dechet CB, Sebo T, Farrow G, Blute ML, Engen DE, Zincke H. Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults. J Urol. Oct 1999;162(4):1282-4; discussion 1284-5. [Medline].

  8. Link RE, Bhayani SB, Allaf ME, et al. Exploring the learning curve, pathological outcomes and perioperative morbidity of laparoscopic partial nephrectomy performed for renal mass. J Urol. May 2005;173(5):1690-4. [Medline].

  9. Antonelli A, Cozzoli A, Simeone C, et al. Surgical treatment of adrenal metastasis from renal cell carcinoma: a single-centre experience of 45 patients. BJU Int. Mar 2006;97(3):505-8. [Medline].

  10. Yokoyama H, Tanaka M. Incidence of adrenal involvement and assessing adrenal function in patients with renal cell carcinoma: is ipsilateral adrenalectomy indispensable during radical nephrectomy?. BJU Int. Mar 2005;95(4):526-9. [Medline].

  11. Golimbu M, Joshi P, Sperber A, Tessler A, Al-Askari S, Morales P. Renal cell carcinoma: survival and prognostic factors. Urology. Apr 1986;27(4):291-301. [Medline].

  12. Hegarty NJ, Gill IS, Desai MM, Remer EM, O'Malley CM, Kaouk JH. Probe-ablative nephron-sparing surgery: cryoablation versus radiofrequency ablation. Urology. Jul 2006;68(1 Suppl):7-13. [Medline].

  13. Kaouk JH, Aron M, Rewcastle JC, Gill IS. Cryotherapy: clinical end points and their experimental foundations. Urology. Jul 2006;68(1 Suppl):38-44. [Medline].

  14. Al-Qudah HS, Rodriguez AR, Sexton WJ. Laparoscopic management of kidney cancer: updated review. Cancer Control. Jul 2007;14(3):218-30. [Medline][Full Text].

  15. Atwell TD, Farrell MA, Leibovich BC, Callstrom MR, Chow GK, Blute ML. Percutaneous renal cryoablation: experience treating 115 tumors. J Urol. Jun 2008;179(6):2136-40; discussion 2140-1. [Medline].

  16. Clayman RV, Surya V, Miller RP, Reinke DB, Fraley EE. Pursuit of the renal mass. Is ultrasound enough?. Am J Med. Aug 1984;77(2):218-23. [Medline].

  17. Cookson MS. Radical Nephrectomy. In: Graham Jr SD, Glenn JF, eds. Glenn's Urologic Surgery. 5th ed. Philadelphia, Pa: Lippincott-Raven; 1998:61-72.

  18. Cooney MM, Remick SC, Vogelzang NJ. Promising systemic therapy for renal cell carcinoma. Curr Treat Options Oncol. Sep 2005;6(5):357-65. [Medline].

  19. Desai MM, Strzempkowski B, Matin SF, et al. Prospective randomized comparison of transperitoneal versus retroperitoneal laparoscopic radical nephrectomy. J Urol. Jan 2005;173(1):38-41. [Medline].

  20. Finley DS, Beck S, Box G, Chu W, Deane L, Vajgrt DJ. Percutaneous and laparoscopic cryoablation of small renal masses. J Urol. Aug 2008;180(2):492-8; discussion 498. [Medline].

  21. Flaherty KT, Fuchs CS, Colditz GA, et al. A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). Cancer Causes Control. Nov 2005;16(9):1099-106. [Medline].

  22. Gill IS, Clayman RV, McDougall EM. Advances in urological laparoscopy. J Urol. Oct 1995;154(4):1275-94. [Medline].

  23. Gill IS, McClennan BL, Kerbl K, Carbone JM, Wick M, Clayman RV. Adrenal involvement from renal cell carcinoma: predictive value of computerized tomography. J Urol. Oct 1994;152(4):1082-5. [Medline].

  24. Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol. Mar 1990;143(3):468-73; discussion 473-4. [Medline].

  25. Harryman OA, Davenport K, Keoghane S, Keeley FX, Timoney AG. A comparative study of quality of life issues relating to open versus laparoscopic nephrectomy: a prospective pragmatic study. J Urol. Mar 2009;181(3):998-1003; discussion 1003. [Medline].

  26. Hinman F. 1998. In: Atlas of Urologic Surgery. 2nd ed. Philadelphia, Pa: WB Saunders; 853-1056.

  27. Ishikawa I, Honda R, Yamada Y, Kakuma T. Renal cell carcinoma detected by screening shows better patient survival than that detected following symptoms in dialysis patients. Ther Apher Dial. Dec 2004;8(6):468-73. [Medline].

  28. Jacobsohn KM, Wood CG. Adjuvant therapy for renal cell carcinoma. Semin Oncol. Oct 2006;33(5):576-82. [Medline].

  29. Jennings SB, Linehan WM. Renal, Perirenal, and Ureteral Neoplasms. In: Gillenwater JJ, Grayhack JT, Howards SS, Ducket JW. Adult and Pediatric Urology. 3rd ed. St. Louis: Mo: Mosby; 1996:643-94.

  30. Kabalin JN. Surgical anatomy of the retroperitoneum, kidneys, and ureters. In: Walsh PC, Vaughan Jr D, Wein AJ, Retik AB, Zorab R. Campbell's Urology. Vol 1. 7th ed. Philadelphia, Pa: WB Saunders; 1998:49-88.

  31. Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys. May 1987;13(5):665-72. [Medline].

  32. Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients (1982-1997). Urology. Jul 2000;56(1):58-62. [Medline].

  33. Malaeb BS, Martin DJ, Littooy FN, et al. The utility of screening renal ultrasonography: identifying renal cell carcinoma in an elderly asymptomatic population. BJU Int. May 2005;95(7):977-81. [Medline].

  34. McLaughlin JK, Lipworth L, Tarone RE. Epidemiologic aspects of renal cell carcinoma. Semin Oncol. Oct 2006;33(5):527-33. [Medline].

  35. Mevorach RA, Segal AJ, Tersegno ME, Frank IN. Renal cell carcinoma: incidental diagnosis and natural history: review of 235 cases. Urology. Jun 1992;39(6):519-22. [Medline].

  36. Novick AC. Partial nephrectomy for renal cell carcinoma. Urol Clin North Am. May 1987;14(2):419-33. [Medline].

  37. Novick AC, Streem SB. Surgery of the kidney. In: Walsh PC, Vaughan Jr D, Wein AJ, Retik AB, Zorab R, eds. Campbell's Urology. Vol 3. 7th ed. Philadelphia, Pa: WB Saunders; 1998:2973-3051.

  38. O'Malley RL, Godoy G, Kanofsky JA, Taneja SS. The necessity of adrenalectomy at the time of radical nephrectomy: a systematic review. J Urol. May 2009;181(5):2009-17. [Medline].

  39. Ono Y, Hattori R, Gotoh M, Yoshino Y, Yoshikawa Y, Kamihira O. Laparoscopic radical nephrectomy for renal cell carcinoma: the standard of care already?. Curr Opin Urol. Mar 2005;15(2):75-8. [Medline].

  40. Parmar S, Rademaker AW, Fung BB, Kozlowski JM, Kuzel TM. Implications of therapy choice on overall survival in metastatic renal cell carcinoma: a single institution experience. Med Oncol. 2005;22(4):399-405. [Medline].

  41. Peycelon M, Hupertan V, Comperat E, Renard-Penna R, Vaessen C, Conort P. Long-term outcomes after nephron sparing surgery for renal cell carcinoma larger than 4 cm. J Urol. Jan 2009;181(1):35-41. [Medline].

  42. Pizzocaro G, Piva L, Costa A. Adjuvant interferon to radical nephrectomy in Robson's stage II and III renal cell cancer, a multicenter randomized study with some biological evaluations. Proc Am Soc Clin Oncol. 1997;16:318A.

  43. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol. Mar 1969;101(3):297-301. [Medline].

  44. Rodriguez A, Sexton WJ. Management of locally advanced renal cell carcinoma. Cancer Control. Jul 2006;13(3):199-210. [Medline].

  45. Rodriguez R, Chan DY, Bishoff JT, et al. Renal ablative cryosurgery in selected patients with peripheral renal masses. Urology. Jan 2000;55(1):25-30. [Medline].

  46. Simmons MN, Weight CJ, Gill IS. Laparoscopic radical versus partial nephrectomy for tumors >4 cm: intermediate-term oncologic and functional outcomes. Urology. May 2009;73(5):1077-82. [Medline].

  47. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol. Jan 2005;173(1):48-51. [Medline].

  48. Steinberg AP, Finelli A, Desai MM, et al. Laparoscopic radical nephrectomy for large (greater than 7 cm, T2) renal tumors. J Urol. Dec 2004;172(6 Pt 1):2172-6. [Medline].

  49. Tosaka A, Ohya K, Yamada K, et al. Incidence and properties of renal masses and asymptomatic renal cell carcinoma detected by abdominal ultrasonography. J Urol. Nov 1990;144(5):1097-9. [Medline].

  50. Tsui KH, Shvarts O, Smith RB, Figlin R, de Kernion JB, Belldegrun A. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol. Feb 2000;163(2):426-30. [Medline].

  51. Varkarakis IM, Bhayani SB, Allaf ME, Inagaki T, Gonzalgo ML, Jarrett TW. Laparoscopic-assisted nephrectomy with inferior vena cava tumor thrombectomy: preliminary results. Urology. Nov 2004;64(5):925-9. [Medline].

  52. Wagner JR, Walther MM, Linehan WM, White DE, Rosenberg SA, Yang JC. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol. Jul 1999;162(1):43-5. [Medline].

  53. Zeman RK, Cronan JJ, Rosenfield AT, Lynch JH, Jaffe MH, Clark LR. Renal cell carcinoma: dynamic thin-section CT assessment of vascular invasion and tumor vascularity. Radiology. May 1988;167(2):393-6. [Medline].

Further Reading

Keywords

radical nephrectomy, simple nephrectomy, kidney disease, kidney resection, radical kidney surgery, renal cell carcinoma, RCC, localized renal cell carcinoma, renovascular hypertension, renal artery disease, parenchymal damage, nephrosclerosis, pyelonephritis, reflux dysplasia, congenital dysplasia of the kidney, congenital kidney dysplasia, renal dysplasia, kidney dysplasia, renal lesion, simple nephrectomy, renal cyst, renal cancer, renal cell cancer, irreversible kidney damage, calculus disease, nephron-sparing surgery, NSS, partial nephrectomy, laparoscopic partial nephrectomy

Contributor Information and Disclosures

Author

Richard A Santucci, MD, FACS, Chief of Urology, Detroit Receiving Hospital; Specialist-in-Chief of Urology, Detroit Medical Center; Chief of Urologic Trauma Surgery, Sinai Grace Hospital; Director, The Center for Urologic Reconstruction; Clinical Professor of Urology, Michigan State College of Medicine
Richard A Santucci, MD, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, and Société Internationale d'Urologie (International Society of Urology)
Disclosure: Nothing to disclose.

Coauthor(s)

Hosam S Al-Qudah, MD, Consultant Urologist, Department of General Surgery, Saad Specialist Hospital, Al-Khobar, Saudi Arabia
Disclosure: Nothing to disclose.

Medical Editor

Michael Grasso, MD, Chairman, Department of Urology, Saint Vincent's Medical Center; Professor and Vice Chairman, Department of Urology, New York Medical College
Michael Grasso, MD is a member of the following medical societies: American Medical Association, American Urological Association, California Medical Association, and Endourological Society
Disclosure: Karl Storz Endoscopy Consulting fee Consulting; Boston Scientific Consulting fee Consulting; Cook Urologic Consulting fee Consulting

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Martin I Resnick, MD †, Former Lester Persky Professor and Chair, Department of Urology, Former Professor, Department of Oncology, Case Western Reserve University School of Medicine
Martin I Resnick, MD † is a member of the following medical societies: American College of Surgeons, American Federation for Medical Research, American Institute of Ultrasound in Medicine, American Medical Association, American Society for Bone and Mineral Research, American Society for Reproductive Medicine, American Society of Andrology, American Surgical Association, American Urological Association, Association for Academic Surgery, Endocrine Society, National Kidney Foundation, Ohio Urological Society, and Pan American Medical Association
Disclosure: Nothing to disclose.

CME Editor

J Stuart Wolf Jr, MD, FACS, David A Bloom Professor of Urology, Director of Division of Minimally Invasive Urology, Department of Urology, University of Michigan
J Stuart Wolf Jr, MD, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Catholic Medical Association, Endourological Society, Society for Urology and Engineering, Society of Laparoendoscopic Surgeons, Society of University Urologists, and Society of Urologic Oncology
Disclosure: Terumo Corporation Consulting fee Consulting; Gyrus-ACMI Honoraria Speaking and teaching

Chief Editor

Bradley Fields Schwartz, DO, FACS, Professor of Urology, Director, Center for Laparoscopy and Endourology, Department of Surgery, Southern Illinois University School of Medicine
Bradley Fields Schwartz, DO, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Association of Military Osteopathic Physicians and Surgeons, Endourological Society, Society of Laparoendoscopic Surgeons, and Society of University Urologists
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.